The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi. The biosimilar of IL-6 inhibitor …
Read Full Story at source (may require registration)
- How to Sell a Small Business: A Starter Guide for Business Owners - February 3, 2025
- European Shares Drift Lower Amid France’s Debt Woes - November 27, 2024
- FTSE 100 Modestly Higher In Cautious Trade - November 27, 2024